SpyGlass Pharma, Inc. Common Stock SGP · SEC Filings

website

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative th...

Price38.37

Market Cap1.28 B

Float13.97 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 26, 2026

News

TYPE

HEADLINE

FILED AT

8-K

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

Oct 19, 2026

8-K

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS)

Oct 1, 2026

8-K

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Corporate Updates

Aug 6, 2026

8-K

SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 14, 2026

8-K

SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides Corporate Update

Mar 26, 2026

8-K

SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its BIM-IOL System

Mar 9, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 6, 2026

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Feb 5, 2026

S-1/A

OFFERING | Bank: Jefferies, Leerink Partners, Citigroup, Stifel

Jan 29, 2026

S-1

OFFERING | Bank: Jefferies, Leerink Partners, Citigroup, Stifel

Jan 16, 2026

DRS/A

Form DRS/A - Draft Registration Statement: [Amend]

Dec 9, 2025

DRS

Form DRS - Draft Registration Statement

Sep 26, 2025

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

Samsara BioCapital, L.P. (Filed by)

Feb 17, 2026

SCHEDULE 13D

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Feb 17, 2026

SCHEDULE 13D

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Feb 13, 2026

SCHEDULE 13D

Gilde Healthcare Holding B.V. (Filed by)

Feb 13, 2026

SCHEDULE 13G

Sands Capital Life Sciences Pulse Fund III (DE), L.P. (Filed by)

Feb 13, 2026

RA Capital Healthcare Fund LP (Reporting)

Feb 11, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 2, 2026

CORRESP

Form CORRESP - Correspondence

Jan 29, 2026

CORRESP

Form CORRESP - Correspondence

Jan 29, 2026

CORRESP

Form CORRESP - Correspondence

Jan 29, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jan 27, 2026

CORRESP

Form CORRESP - Correspondence

Jan 16, 2026